Back to top
more

Immunocore (IMCR)

(Delayed Data from NSDQ)

$37.40 USD

37.40
257,044

+0.79 (2.16%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $37.37 -0.03 (-0.08%) 6:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Immunocore (IMCR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.

Zacks Equity Research

Perrigo to Report Q3 Earnings: Is a Beat in Store for the Stock?

by Zacks Equity Research

PRGO is likely to post Q3 results as strategic price hikes lift sales, but exited lines and macro pressures may weigh on performance.

Zacks Equity Research

Intellia Gears Up to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

NTLA's third-quarter results are likely to reflect progress on the CRISPR pipeline, with focus on ATTR studies and progress in HAE therapy filing.

Zacks Equity Research

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

by Zacks Equity Research

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

Zacks Equity Research

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

by Zacks Equity Research

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

Zacks Equity Research

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

by Zacks Equity Research

NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.

Zacks Equity Research

PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

by Zacks Equity Research

Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.

Zacks Equity Research

MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

by Zacks Equity Research

Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.

Zacks Equity Research

Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.